<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36762927</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-3686</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><MedlineDate>2023 Mar-Apr 01</MedlineDate></PubDate></JournalIssue><Title>American journal of therapeutics</Title><ISOAbbreviation>Am J Ther</ISOAbbreviation></Journal><ArticleTitle>Ivermectin and the Emergence of Long COVID.</ArticleTitle><Pagination><StartPage>e145</StartPage><MedlinePgn>e145</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MJT.0000000000001607</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manu</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY and South Oaks Hospital, Amityville, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ther</MedlineTA><NlmUniqueID>9441347</NlmUniqueID><ISSNLinking>1075-2765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="Y">Ivermectin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36762927</ArticleId><ArticleId IdType="doi">10.1097/MJT.0000000000001607</ArticleId><ArticleId IdType="pii">00045391-990000000-00116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023:1&#x2013;14.</Citation></Reference><Reference><Citation>https://abcnews.go.com/Health/controversial-doctor-group-touts-ivermectin-long-covid-treatment/story?id=82967318 (Posted February 18, 2022; Accessed January 18, 2023).</Citation></Reference><Reference><Citation>https://www.statnews.com/2022/07/26/ivermectin-has-become-a-popular-treatment-for-long-covid-with-a-push-from-doctors-with-ties-to-right-wing-political-groups/ (Posted July 26, 2022; Accessed January 18, 2023).</Citation></Reference><Reference><Citation>https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/ (Updated Apr 29, 2022; Accessed Sep 16, 2022).</Citation></Reference><Reference><Citation>https://emergency.cdc.gov/newsletters/coca/020122.htm (Updated Feb1, 2022; Accessed Sep 16, 2022).</Citation></Reference><Reference><Citation>Naggie S, Boulware DR, Lindsell CJ, et al. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV-6) study group and investigators. Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;328:1595&#x2013;1603.</Citation></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al., COVID-OUT Trial Team. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19. N Engl J Med. 2022;387:599&#x2013;610.</Citation></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz D, et al. Outpatient Treatment of Covid-19 with Metformin, Ivermectin, and Fluvoxamine and the Development of Long Covid over 10-month Follow-Up; 2022. medRxiv [Preprint].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>